Outset Medical (OM) Stock Price, News & Analysis

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Outset Medical in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OM, but not buy additional shares or sell existing shares.
View OM analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month target prices for Outset Medical's shares. Their OM share price targets range from $3.00 to $6.00. On average, they predict the company's stock price to reach $5.42 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts price targets for OM or view top-rated stocks among Wall Street analysts.

Outset Medical's stock was trading at $5.41 at the beginning of 2024. Since then, OM stock has decreased by 57.7% and is now trading at $2.29.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our OM earnings forecast.

Outset Medical, Inc. (NASDAQ:OM) posted its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.74) by $0.03. The business had revenue of $30.51 million for the quarter, compared to analysts' expectations of $30.40 million. Outset Medical had a negative net margin of 132.54% and a negative trailing twelve-month return on equity of 102.50%.

ETFs with the largest weight of Outset Medical (NASDAQ:OM) stock in their portfolio include Procure Disaster Recovery Strategy ETF (FIXT), Procure Disaster Recovery Strategy ETF (FEMA) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Medical Devices ETF (IHI).

Outset Medical issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $145.0 million-$153.0 million, compared to the consensus revenue estimate of $148.8 million.

Outset Medical (OM) raised $175 million in an initial public offering on Tuesday, September 15th 2020. The company issued 7,600,000 shares at a price of $22.00-$24.00 per share. BofA Securities, Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

Outset Medical's stock is owned by many different institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (0.19%). Insiders that own company stock include D Keith Grossman, James F Hinrichs, James F Hinrichs, Jean-Olivier Racine, John L Brottem, John L Brottem, Leslie Trigg, Marc Nash, Martin Vazquez, Nabeel Ahmed, Rebecca Chambers, Stacey L Porter and Steven S Williamson.
View institutional ownership trends.

Shares of OM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.